Clinical Trials Logo

Vaginal Cancer clinical trials

View clinical trials related to Vaginal Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06314568 Recruiting - Vaginal Cancer Clinical Trials

Radiochemotherapy and Interventional Radiotherapy in Vaginal Cancer

TRIDENT
Start date: March 15, 2024
Phase:
Study type: Observational

Prospective observational multicenter study, aimed at evaluating the effectiveness on local control and cancer-specific survival of radiochemotherapy followed by interventional radiotherapy in patients affected by vaginal cancer

NCT ID: NCT06203106 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

NYSCF Scientific Discovery Biobank

Start date: November 10, 2022
Phase:
Study type: Observational

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.

NCT ID: NCT05979610 Recruiting - Cervical Cancer Clinical Trials

Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies

Reiki-Brachy
Start date: October 9, 2023
Phase: Phase 2
Study type: Interventional

The goal of this open label, randomized, controlled clinical trial is to assess the benefits of providing Reiki therapy to subjects receiving their first brachytherapy treatment for gynecological malignancies. Participants will either receive a session of Reiki therapy or usual care during the standard wait time between the placement of the brachytherapy device and brachytherapy treatment. Questionnaires will be administered at various time points on the day of the participant's first brachytherapy treatment as well as at the three month follow-up time point. Researchers will compare the intervention (Reiki therapy) and control (usual care) groups to assess the impact of the Reiki therapy on anxiety, pain, state anxiety, depression, and physiological measurements.

NCT ID: NCT05743517 Recruiting - Cervical Cancer Clinical Trials

Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)

Start date: September 15, 2023
Phase: N/A
Study type: Interventional

The primary purpose of the study is to determine which of four components (symptom-burden tailored app, exercise partner, oncology provider engagement, coaching) added to a core intervention of a wearable activity tracker and commercially available app, will improve physical activity. The findings will generate meaningful knowledge about how to best increase physical activity in older gynecologic cancer patients receiving systemic cancer therapies to improve quality of life and cancer-specific survival.

NCT ID: NCT05686226 Recruiting - Cervical Cancer Clinical Trials

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Start date: March 7, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.

NCT ID: NCT05561413 Recruiting - Cervical Cancer Clinical Trials

Gynaecology Exercise and Mindfulness Study

GEMS
Start date: June 14, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to explore the feasibility and effectiveness of conducting a mindfulness and home-based walking and strength training program on fatigue, psychological outcomes and quality of life for gynecological cancer survivors. The intervention consists of a 8 week mindfulness and home based walking and strengthening program for gynecology survivors. It will be delivered through a specifically designed app. The aim would be to gradually increase exercise and mindfulness levels so participants start to achieve the recommended levels of activity per week. Participants will be recruited via cancer Charites and their service users either directly and through social media (Facebook, Instagram, Twitter). Both groups will receive an intervention either mindfulness alone or mindfulness and exercise. Assessments will be taken at baseline (0 weeks) and post intervention (8 weeks). Both groups will complete the same assessments at the same time-points.

NCT ID: NCT05371353 Recruiting - Vaginal Cancer Clinical Trials

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Start date: May 14, 2022
Phase:
Study type: Observational

To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.

NCT ID: NCT05242861 Recruiting - Ovarian Neoplasms Clinical Trials

Retrospective Study of Brachytherapy

RetroBT
Start date: February 20, 2022
Phase:
Study type: Observational

Brachytherapy for gynecological cancers will be studied retrospectively.

NCT ID: NCT05027776 Recruiting - Vaginal Cancer Clinical Trials

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Start date: September 15, 2021
Phase: Phase 3
Study type: Interventional

This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years

NCT ID: NCT04977453 Recruiting - Clinical trials for Non-small Cell Lung Cancer

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Start date: August 2, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab, lenvatinib or local radiotherapy (RT) over a range of advanced and/or metastatic solid tumors.